Merck KGaA has taken steps to bolster its immuno-oncology portfolio with the signing of an option and collaboration agreement with F-star Biotechnology Ltd to develop five bispecific antibody compounds. A bispecific antibody is an engineered molecule that binds to two different antigens.
